Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_assertion type Assertion NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_head.
- NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_assertion description "[If the diagnostic cutoff value of ANXA2 level was more than 18 ng/mL, the incidence of serum ANXA2 was 86.96% in the HCC group, 80% in the metastatic liver cancer group, 31.58% in the liver cirrhosis group, none in the chronic hepatitis or acute hepatitis or normal control group, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_provenance.
- NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_assertion evidence source_evidence_literature NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_provenance.
- NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_assertion SIO_000772 23139605 NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_provenance.
- NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_assertion wasDerivedFrom befree-20140225 NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_provenance.
- NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_assertion wasGeneratedBy ECO_0000203 NP615557.RArWUDzZs0C3JggDp8kGVsfdz4mqx6tq2Nt5VHRAtwQdc130_provenance.